<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768647</url>
  </required_header>
  <id_info>
    <org_study_id>N3397-R</org_study_id>
    <secondary_id>1I01RX003397</secondary_id>
    <nct_id>NCT04768647</nct_id>
  </id_info>
  <brief_title>Vestibulopathy as a Cause of Imbalance in Parkinson</brief_title>
  <official_title>Vestibulopathy, Imbalance and Gait Disturbances in Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Balance problems and falls are common in people with Parkinson's disease but respond poorly&#xD;
      to dopamine stimulating medications suggesting other causes. The main goal of this study is&#xD;
      to assess whether imbalance and gait problems in people with Parkinson's disease may be&#xD;
      related to vestibular (inner ear balance center) changes not related to loss of dopamine in&#xD;
      the brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by resting&#xD;
      tremor, slowness of movement, rigidity as well as postural instability and gait difficulties&#xD;
      (PIGD) motor features. Nigrostriatal dopaminergic denervation is a key pathological factor in&#xD;
      PD. Advancing PD is associated with disabling PIGD motor features, in particular freezing of&#xD;
      gait (FoG). This is further complicated by fear of falling resulting in pervasive&#xD;
      sedentariness where avoidance of physical activity leads to deconditioning, thereby&#xD;
      aggravating a downward functional spiral. The dopaminergic medication-refractory nature of&#xD;
      PIGD motor features in advancing PD implicates non-dopaminergic brain pathologies.&#xD;
&#xD;
      The investigators have novel preliminary data showing that non-acute vestibulopathy may be&#xD;
      another important factor contributing to PIGD motor features in PD. Unlike sporadic&#xD;
      intermittent vestibular disorders with a more acute onset, chronic bilateral vestibular&#xD;
      dysfunction of older age. The investigators preliminary data suggest that vestibulopathy may&#xD;
      be a critical determinant of imbalance and gait problems in PD (scientific premise). However,&#xD;
      these preliminary observations need to be confirmed in a larger study using more dedicated&#xD;
      assessment methods (knowledge gap). Closing this gap is important because of the potentially&#xD;
      high clinical translational impact if preliminary findings can be verified. The investigators&#xD;
      will also explore whether stimulation of the vestibular system may help to improve PIGD in a&#xD;
      small exploratory pilot biomechanistic sub-study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vestibular function</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
    <description>Assessment of vestibular functions using standard vestibular testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Imbalance score</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Clinical imbalance motor score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DAT brain PET</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Dopamine transporter PET</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Main cohort</arm_group_label>
    <description>Main cohort of all patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subgroup of patients with imbalance</arm_group_label>
    <description>Subgroup of patients with imbalance</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TNM</intervention_name>
    <description>TNM is a small portable head set that can be used by the participants at home to stimulate the vestibular system</description>
    <arm_group_label>Subgroup of patients with imbalance</arm_group_label>
    <other_name>Thermoneuromodulation</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Veterans with Parkinson's disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PD based on the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic&#xD;
             Research Criteria (n=64, gross recruitment)&#xD;
&#xD;
          -  M/F&#xD;
&#xD;
          -  age 45 years or older&#xD;
&#xD;
          -  duration of disease &gt; 5 years and/or Hoehn &amp; Yahr stages 1.5-4 able to ambulate&#xD;
             independently and no evidence of dementia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of Meniere disease or recent onset of acute vestibular dysfunction, such as&#xD;
             otolith disorders (BBPV etc).&#xD;
&#xD;
          -  Other disorders which may resemble PD, such as progressive supranuclear palsy (PSP),&#xD;
             vascular dementia, normal pressure hydrocephalus, multiple system atrophy (MSA),&#xD;
             corticobasal ganglionic degeneration, or toxic causes of parkinsonism. Prototypical&#xD;
             cases have distinctive clinical profiles, like early and severe dysautonomia (MSA) or&#xD;
             appendicular apraxia, which may differentiate them from idiopathic PD and PSP. The use&#xD;
             of the UKPDSBRC clinical diagnostic criteria for PD will mitigate the inclusion of&#xD;
             subjects with atypical parkinsonism.&#xD;
&#xD;
          -  Evidence of a stroke or mass lesion on structural brain imaging (MRI).&#xD;
&#xD;
          -  Participants in whom MRI is contraindicated including, but not limited to, those with&#xD;
             a pacemaker, presence of metallic fragments near the eyes or spinal cord, or cochlear&#xD;
             implant.&#xD;
&#xD;
          -  Severe claustrophobia precluding MR or PET imaging.&#xD;
&#xD;
          -  Subjects limited by participation in research procedures involving ionizing radiation.&#xD;
&#xD;
          -  Pregnancy (test within 48 hours of each PET session) or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaas I Bohnen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Ann Arbor Healthcare System, Ann Arbor, MI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolaas I Bohnen, MD PhD</last_name>
    <phone>(734) 769-7100</phone>
    <email>nicolaas.bohnen@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linda Rubley</last_name>
      <phone>734-998-8400</phone>
      <email>rubleyls@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Ann Arbor Healthcare System, Ann Arbor, MI</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolaas I Bohnen, MD PhD</last_name>
      <phone>734-769-7100</phone>
      <email>nicolaas.bohnen@va.gov</email>
    </contact>
    <investigator>
      <last_name>Nicolaas I Bohnen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dopamine</keyword>
  <keyword>imbalance</keyword>
  <keyword>vestibular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

